Estimating and Modelling the Proportion Cured of Disease in Population Based Cancer Studies

Similar documents
Overview. All-cause mortality for males with colon cancer and Finnish population. Relative survival

Estimating and modelling relative survival

Quantifying cancer patient survival; extensions and applications of cure models and life expectancy estimation

The improved cure fraction for esophageal cancer in Linzhou city

Downloaded from:

Up-to-date survival estimates from prognostic models using temporal recalibration

Biological Cure. Margaret R. Stedman, Ph.D. MPH Angela B. Mariotto, Ph.D.

Sarwar Islam Mozumder 1, Mark J Rutherford 1 & Paul C Lambert 1, Stata London Users Group Meeting

About me. An overview and some recent advances in statistical methods for population-based cancer survival analysis. Research interests

MEASURING CANCER CURE IN IRELAND

Application of EM Algorithm to Mixture Cure Model for Grouped Relative Survival Data

Issues for analyzing competing-risks data with missing or misclassification in causes. Dr. Ronny Westerman

Assessment of lead-time bias in estimates of relative survival for breast cancer

IJC International Journal of Cancer

An overview and some recent advances in statistical methods for population-based cancer survival analysis

Downloaded from irje.tums.ac.ir at 19:49 IRST on Monday January 14th 2019

Period estimates of cancer patient survival are more up-to-date than complete estimates even at comparable levels of precision

M. J. Rutherford 1,*, T. M-L. Andersson 2, H. Møller 3, P.C. Lambert 1,2.

Trends in Cure Fraction from Colorectal Cancer by Age and Tumour Stage Between 1975 and 2000, Using Population-based Data, Osaka, Japan

Measuring and predicting cancer incidence, prevalence and survival in Finland

Statistical Models for Censored Point Processes with Cure Rates

Estimating relative survival using the strel command

Case Studies in Bayesian Augmented Control Design. Nathan Enas Ji Lin Eli Lilly and Company

Analysing population-based cancer survival settling the controversies

Temporal trends in the proportion cured for cancer of the colon and rectum: A population-based study using data from the Finnish Cancer Registry

Benchmark Dose Modeling Cancer Models. Allen Davis, MSPH Jeff Gift, Ph.D. Jay Zhao, Ph.D. National Center for Environmental Assessment, U.S.

Survival Prediction Models for Estimating the Benefit of Post-Operative Radiation Therapy for Gallbladder Cancer and Lung Cancer

Methodology for the Survival Estimates

Original Article INTRODUCTION. Alireza Abadi, Farzaneh Amanpour 1, Chris Bajdik 2, Parvin Yavari 3

D ifferences in colorectal cancer survival between

LOGO. Statistical Modeling of Breast and Lung Cancers. Cancer Research Team. Department of Mathematics and Statistics University of South Florida

Supplementary Information for Avoidable deaths and random variation in patients survival

Cure fraction model with random effects for regional variation in cancer survival

Supplement for: CD4 cell dynamics in untreated HIV-1 infection: overall rates, and effects of age, viral load, gender and calendar time.

Biostatistics II

Survival in Teenagers and Young. Adults with Cancer in the UK

Multivariate dose-response meta-analysis: an update on glst

Extract from Cancer survival in Europe by country and age: results of EUROCARE-5 a population-based study

The Statistical Analysis of Failure Time Data

Cross-validated AUC in Stata: CVAUROC

ASSESSMENT OF LEAD-TIME BIAS IN ESTIMATES OF RELATIVE SURVIVAL FOR BREAST CANCER

Cancer Incidence Predictions (Finnish Experience)

Assessing methods for dealing with treatment switching in clinical trials: A follow-up simulation study

Joint Modelling of Event Counts and Survival Times: Example Using Data from the MESS Trial

Relative Survival of Breast Cancer Patients in Iran

Long-term survival of cancer patients in Germany achieved by the beginning of the third millenium

Age-standardised Net Survival & Cohort and Period Net Survival Estimates

An Overview of Survival Statistics in SEER*Stat

Multi-state survival analysis in Stata

Breast cancer survival, competing risks and mixture cure model: a Bayesian analysis

Introduction to Survival Analysis Procedures (Chapter)

Downloaded from:

Modelled prevalence. Marc COLONNA. January 22-23, 2014 Ispra

Lead team presentation Brentuximab vedotin for relapsed or refractory systemic anaplastic large cell lymphoma (STA)

R. Schaffar 1*, A. Belot 2, B. Rachet 2 and L. Woods 2

Downloaded from:

Modeling unobserved heterogeneity in Stata

Appendix NEW METHOD FOR ESTIMATING HIV INCIDENCE AND TIME FROM INFECTION TO DIAGNOSIS USING HIV SURVEILLANCE DATA: RESULTS FOR FRANCE

Cancer survival and prevalence in Tasmania

prevalence: Ispra Jan 23, 2014

Current Estimates of the Cure Fraction: A Feasibility Study of Statistical Cure for Breast and Colorectal Cancer

Bayesian Estimations from the Two-Parameter Bathtub- Shaped Lifetime Distribution Based on Record Values

A note on Australian AIDS survival

Lizet Sanchez 1*, Patricia Lorenzo-Luaces 1, Carmen Viada 1, Yaima Galan 2, Javier Ballesteros 3, Tania Crombet 4 and Agustin Lage 5*

Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008

Recent Advances in Methods for Quantiles. Matteo Bottai, Sc.D.

NICER. Trends in Prostate Cancer Survival in Switzerland

Do morphology and stage explain the inferior lung cancer survival in Denmark?

Population Based Survival of Female Breast Cancer Cases in Riyadh Region, Saudi Arabia

Surgeon workload and survival from breast cancer

The EUROCARE Study: strengths, limitations and perspectives of population-based, comparative survival studies

AN INDEPENDENT VALIDATION OF QRISK ON THE THIN DATABASE

List of Figures. List of Tables. Preface to the Second Edition. Preface to the First Edition

DISEASE-SPECIFIC REFERENCE EQUATIONS FOR LUNG FUNCTION IN PATIENTS WITH CYSTIC FIBROSIS

cloglog link function to transform the (population) hazard probability into a continuous

Modern Regression Methods

Investigation of relative survival from colorectal cancer between NHS organisations

Propensity scores: what, why and why not?

Downloaded from jhs.mazums.ac.ir at 13: on Friday July 27th 2018 [ DOI: /acadpub.jhs ]

Vincent Y. F. He 1*, John R. Condon 1, Peter D. Baade 1,2, Xiaohua Zhang 3 and Yuejen Zhao 3

Estimands, Missing Data and Sensitivity Analysis: some overview remarks. Roderick Little

The NCPE has issued a recommendation regarding the use of pertuzumab for this indication. The NCPE do not recommend reimbursement of pertuzumab.

THE ISSUE OF STAGE AT DIAGNOSIS

with Stata Bayesian Analysis John Thompson University of Leicester A Stata Press Publication StataCorp LP College Station, Texas

An overview and some recent advances in statistical methods for population-based cancer survival analysis

Package speff2trial. February 20, 2015

ESM1 for Glucose, blood pressure and cholesterol levels and their relationships to clinical outcomes in type 2 diabetes: a retrospective cohort study

Comparison Cure Rate Models by DIC Criteria in Breast Cancer Data

Cross-validation. Miguel Angel Luque Fernandez Faculty of Epidemiology and Population Health Department of Non-communicable Diseases.

OPERATIONAL RISK WITH EXCEL AND VBA

A Simple Stochastic Stomach Cancer Model with Application

STATISTICAL APPENDIX

Supplementary Appendix

Downloaded from:

NICER. Trends in survival from oesophageal cancer in Switzerland

ATTACH YOUR SAS CODE WITH YOUR ANSWERS.

Supplemental Appendix for Beyond Ricardo: The Link Between Intraindustry. Timothy M. Peterson Oklahoma State University

Measuring cancer survival in populations: relative survival vs cancer-specific survival

TWISTED SURVIVAL: IDENTIFYING SURROGATE ENDPOINTS FOR MORTALITY USING QTWIST AND CONDITIONAL DISEASE FREE SURVIVAL. Beth A.

Evaluation of prognostic factors effect on survival time in patients with colorectal cancer, based on Weibull Competing-Risks Model

Transcription:

Estimating and Modelling the Proportion Cured of Disease in Population Based Cancer Studies Paul C Lambert Centre for Biostatistics and Genetic Epidemiology, University of Leicester, UK 12th UK Stata Users Group Meeting London 11th-12th September 2006 Paul C Lambert Cure Models and Relative Survival 12th UK Stata Users Group 1/27

Population Based Cancer Studies Using data from cancer registries. Attempt to obtain all diagnosed cancers. Information used for incidence and survival. Large sample sizes. Relative Survival methods used for survival analysis. Five year relative survival often reported. Paul C Lambert Cure Models and Relative Survival 12th UK Stata Users Group 2/27

Relative Survival Relative Survival = Observed Survival Expected Survival R(t) = S(t)/S (t) Expected survival obtained from national population life tables stratified by age, sex, year of diagnosis, other covariates. Estimate of mortality associated with a disease without requiring information on cause of death. On hazard scale h(t) = h (t) + λ(t) Observed Mortality Rate = Expected Mortality Rate + Excess Mortality Rate Paul C Lambert Cure Models and Relative Survival 12th UK Stata Users Group 3/27

Relative Survival Relative Survival = Observed Survival Expected Survival R(t) = S(t)/S (t) Expected survival obtained from national population life tables stratified by age, sex, year of diagnosis, other covariates. Estimate of mortality associated with a disease without requiring information on cause of death. On hazard scale h(t) = h (t) + λ(t) Observed Mortality Rate = Expected Mortality Rate + Excess Mortality Rate Paul C Lambert Cure Models and Relative Survival 12th UK Stata Users Group 3/27

Relative Survival Relative Survival = Observed Survival Expected Survival R(t) = S(t)/S (t) Expected survival obtained from national population life tables stratified by age, sex, year of diagnosis, other covariates. Estimate of mortality associated with a disease without requiring information on cause of death. On hazard scale h(t) = h (t) + λ(t) Observed Mortality Rate = Expected Mortality Rate + Excess Mortality Rate Paul C Lambert Cure Models and Relative Survival 12th UK Stata Users Group 3/27

Relative Survival Models Usually model on the log excess hazard (mortality) scale[3]. h(t) = h (t) + exp(βx) Parameters are (log) excess hazard ratios. Models have proportional excess hazards as a special case, but often non-proportional excess hazards are observed. Non-proportionality modelled piecewise[3], using fractional polynomials[6], or splines[4]. The models do not assume that a proportion of patients may be cured of their disease. For details of Stata command strs for estimation and modelling of relative survival using piecewise methods see http://www.pauldickman.com/rsmodel/stata_colon/ Paul C Lambert Cure Models and Relative Survival 12th UK Stata Users Group 4/27

Relative Survival Models Usually model on the log excess hazard (mortality) scale[3]. h(t) = h (t) + exp(βx) Parameters are (log) excess hazard ratios. Models have proportional excess hazards as a special case, but often non-proportional excess hazards are observed. Non-proportionality modelled piecewise[3], using fractional polynomials[6], or splines[4]. The models do not assume that a proportion of patients may be cured of their disease. For details of Stata command strs for estimation and modelling of relative survival using piecewise methods see http://www.pauldickman.com/rsmodel/stata_colon/ Paul C Lambert Cure Models and Relative Survival 12th UK Stata Users Group 4/27

Relative Survival Models Usually model on the log excess hazard (mortality) scale[3]. h(t) = h (t) + exp(βx) Parameters are (log) excess hazard ratios. Models have proportional excess hazards as a special case, but often non-proportional excess hazards are observed. Non-proportionality modelled piecewise[3], using fractional polynomials[6], or splines[4]. The models do not assume that a proportion of patients may be cured of their disease. For details of Stata command strs for estimation and modelling of relative survival using piecewise methods see http://www.pauldickman.com/rsmodel/stata_colon/ Paul C Lambert Cure Models and Relative Survival 12th UK Stata Users Group 4/27

Relative Survival Models Usually model on the log excess hazard (mortality) scale[3]. h(t) = h (t) + exp(βx) Parameters are (log) excess hazard ratios. Models have proportional excess hazards as a special case, but often non-proportional excess hazards are observed. Non-proportionality modelled piecewise[3], using fractional polynomials[6], or splines[4]. The models do not assume that a proportion of patients may be cured of their disease. For details of Stata command strs for estimation and modelling of relative survival using piecewise methods see http://www.pauldickman.com/rsmodel/stata_colon/ Paul C Lambert Cure Models and Relative Survival 12th UK Stata Users Group 4/27

Relative Survival Models Usually model on the log excess hazard (mortality) scale[3]. h(t) = h (t) + exp(βx) Parameters are (log) excess hazard ratios. Models have proportional excess hazards as a special case, but often non-proportional excess hazards are observed. Non-proportionality modelled piecewise[3], using fractional polynomials[6], or splines[4]. The models do not assume that a proportion of patients may be cured of their disease. For details of Stata command strs for estimation and modelling of relative survival using piecewise methods see http://www.pauldickman.com/rsmodel/stata_colon/ Paul C Lambert Cure Models and Relative Survival 12th UK Stata Users Group 4/27

Definition of Cure (1) For many cancers the hazard (mortality) rate returns to the same level as that in the general population. When this occurs the relative survival curve is seen to reach a plateau (or the excess hazard rate approaches zero). This is Population or Statististical Cure. Information of cure at the individual level not available. Paul C Lambert Cure Models and Relative Survival 12th UK Stata Users Group 5/27

Definition of Cure (1) For many cancers the hazard (mortality) rate returns to the same level as that in the general population. When this occurs the relative survival curve is seen to reach a plateau (or the excess hazard rate approaches zero). This is Population or Statististical Cure. Information of cure at the individual level not available. Paul C Lambert Cure Models and Relative Survival 12th UK Stata Users Group 5/27

Definition of Cure (1) For many cancers the hazard (mortality) rate returns to the same level as that in the general population. When this occurs the relative survival curve is seen to reach a plateau (or the excess hazard rate approaches zero). This is Population or Statististical Cure. Information of cure at the individual level not available. Paul C Lambert Cure Models and Relative Survival 12th UK Stata Users Group 5/27

Definition of Cure (1) For many cancers the hazard (mortality) rate returns to the same level as that in the general population. When this occurs the relative survival curve is seen to reach a plateau (or the excess hazard rate approaches zero). This is Population or Statististical Cure. Information of cure at the individual level not available. Paul C Lambert Cure Models and Relative Survival 12th UK Stata Users Group 5/27

Definition of Cure (2) 1.0 0.8 Relative Survival 0.6 0.4 0.2 0.0 0 2 4 6 8 10 Time from Diagnosis (Years) Paul C Lambert Cure Models and Relative Survival 12th UK Stata Users Group 6/27

Definition of Cure (2) 1.0 0.8 Relative Survival 0.6 0.4 0.2 0.0 0 2 4 6 8 10 Time from Diagnosis (Years) Paul C Lambert Cure Models and Relative Survival 12th UK Stata Users Group 6/27

Relative Survival for Cancer of the Colon in Finland 1.0 0.8 1953 1964 1965 1974 1975 1984 1985 1994 1995 2003 Relative Survival 0.6 0.4 0.2 0.0 0 2 4 6 8 10 Years from Diagnosis Paul C Lambert Cure Models and Relative Survival 12th UK Stata Users Group 7/27

Mixture and Non-Mixture Models Relative Survival Models S(t) = S (t)r(t) h(t) = h (t) + λ(t) When modelling cure we define an asymptote at the cure fraction, π, for the relative survival function, R(t). The excess hazard rate, λ(t), has an asymptote at zero. Two main approaches Mixture Model Non-Mixture Model Both of these models have been used in standard survival analysis [9], i.e. not incorporating background mortality. Some of these models are implemented in Stata using the cureregr command. Paul C Lambert Cure Models and Relative Survival 12th UK Stata Users Group 8/27

Mixture and Non-Mixture Models Relative Survival Models S(t) = S (t)r(t) h(t) = h (t) + λ(t) When modelling cure we define an asymptote at the cure fraction, π, for the relative survival function, R(t). The excess hazard rate, λ(t), has an asymptote at zero. Two main approaches Mixture Model Non-Mixture Model Both of these models have been used in standard survival analysis [9], i.e. not incorporating background mortality. Some of these models are implemented in Stata using the cureregr command. Paul C Lambert Cure Models and Relative Survival 12th UK Stata Users Group 8/27

Mixture Model Mixture Model S(t) = S (t)(π + (1 π)s u (t)) h(t) = h (t) + (1 π)fu(t) π+(1 π)s u(t) S (t) is the expected survival. π is the proportion cured (the cure fraction). (1 π) is the proportion uncured (those bound to die ). S u (t) is the survival for the uncured group. See De Angelis [2] and Verdecchia [10] for more details. Paul C Lambert Cure Models and Relative Survival 12th UK Stata Users Group 9/27

Non-Mixture Model Non Mixture Model S(t) = S (t)π Fz(t) h(t) = h (t) ln(π)f z (t) We have extended the non-mixture model to relative survival[7]. If parameters in f z (t) do not vary by covariates then this is a proportional excess hazards model. The mixture model does not have proportional excess hazards as a special case. The non-mixture model can also be written as; S(t) = S (t) ( π + (1 π) ( π Fz(t) π) 1 π )) This is a mixture cure fraction model and thus the survival function of uncured patients can also be obtained from a non-mixture model by a simple transformation of the model parameters. Paul C Lambert Cure Models and Relative Survival 12th UK Stata Users Group 10/27

Non-Mixture Model Non Mixture Model S(t) = S (t)π Fz(t) h(t) = h (t) ln(π)f z (t) We have extended the non-mixture model to relative survival[7]. If parameters in f z (t) do not vary by covariates then this is a proportional excess hazards model. The mixture model does not have proportional excess hazards as a special case. The non-mixture model can also be written as; S(t) = S (t) ( π + (1 π) ( π Fz(t) π) 1 π )) This is a mixture cure fraction model and thus the survival function of uncured patients can also be obtained from a non-mixture model by a simple transformation of the model parameters. Paul C Lambert Cure Models and Relative Survival 12th UK Stata Users Group 10/27

Likelihood Relative Survival Models L i = d i ln(h (t i )+λ(t i ))+ ln(s (t i ))+ln(r(t i )) ln(s (t 0i )) ln(r(t 0i )) S (t i ) and S (t 0i ) do not depend on the model parameters and can be excluded from the likelihood. Merge in expected mortality rate at time of death, h (t i ). Newton-Raphson algorithm implemented using Stata ml command (method lf). Incorporating delayed entry allows period analysis models to be fitted[8]. This is a method used to obtain up-to-date estimates of (relative) survival. Application in the cure models allows up-to-date estimates of cure to be obtained. Paul C Lambert Cure Models and Relative Survival 12th UK Stata Users Group 11/27

Likelihood Relative Survival Models L i = d i ln(h (t i )+λ(t i ))+ ln(s (t i ))+ln(r(t i )) ln(s (t 0i )) ln(r(t 0i )) S (t i ) and S (t 0i ) do not depend on the model parameters and can be excluded from the likelihood. Merge in expected mortality rate at time of death, h (t i ). Newton-Raphson algorithm implemented using Stata ml command (method lf). Incorporating delayed entry allows period analysis models to be fitted[8]. This is a method used to obtain up-to-date estimates of (relative) survival. Application in the cure models allows up-to-date estimates of cure to be obtained. Paul C Lambert Cure Models and Relative Survival 12th UK Stata Users Group 11/27

Likelihood Relative Survival Models L i = d i ln(h (t i )+λ(t i ))+ ln(s (t i ))+ln(r(t i )) ln(s (t 0i )) ln(r(t 0i )) S (t i ) and S (t 0i ) do not depend on the model parameters and can be excluded from the likelihood. Merge in expected mortality rate at time of death, h (t i ). Newton-Raphson algorithm implemented using Stata ml command (method lf). Incorporating delayed entry allows period analysis models to be fitted[8]. This is a method used to obtain up-to-date estimates of (relative) survival. Application in the cure models allows up-to-date estimates of cure to be obtained. Paul C Lambert Cure Models and Relative Survival 12th UK Stata Users Group 11/27

strsmix and strsnmix commands strsmix [ varlist ] [ if ] [ in ], distribution(distribution) link(link function) bhazard(varname) [ k1(varlist) k2(varlist) k3(varlist) k4(varlist) pmix(varlist) noconstant noconsk1 noconsk2 noconsk3 noconsk4 noconspmix init(matrix name) skip inititer(#) stopconstraint valconstraint(#) eform ] strsnmix [ varlist ] [ if ] [ in ], distribution(distribution) link(link function) bhazard(varname) [ k1(varlist) k2(varlist) k3(varlist) k4(varlist) pmix(varlist) split(#) earlyk1(varlist) earlyk2(varlist) noconstant noconsk1 noconsk2 noconsk3 noconsk4 noconspmix earlynoconsk1 earlynoconsk2 init(matrix name) skip inititer(#) stopconstraint valconstraint(#) eform ] Stata net from http://www.hs.le.ac.uk/personal/pl4/software/stata/strsnmix install strsnmix Paul C Lambert Cure Models and Relative Survival 12th UK Stata Users Group 12/27

Some options for strsnmix and strsmix distribution(distribution) specifies the parametric distribution. Arguments for both strsmix and strsnmix are weibull, lognomal and gamma, weibexp and weibweib. link(link function) specifies the link function for the cure fraction. Options are identity, logistic and loglog. Note that loglog is ln( ln(π)). bhazard(varname) gives the variable name for the baseline hazard at death/censoring. This option is compulsory, but standard cure models can be estimated by making varname a column of zeros. k1-k4(varlist) gives any covariates for the auxillary parameter. E.g. for the Weibull distribution k1 refers to ln(λ) and k2 refers to ln(γ). Commands submitted to The Stata Journal[5]. Paul C Lambert Cure Models and Relative Survival 12th UK Stata Users Group 13/27

Cancer of the Colon in Finland Data from the Finnish Cancer Registry. 27,754 men and women diagnosed 1953-2003 with follow-up to 2004. Covariates age group and year of diagnosis. Exclude those aged 80 years and over. Use a mixture cure model with Weibull distribution for the uncured. Year of diagnosis modelled using restricted cubic splines for cure fraction and both Weibull parameters. Stata Code strsmix rcs1-rcs4 agegrp2 agegp3 agegrp4 age2rcs1 age3rcs1 age4rcs1, /// dist(weibull) link(identity) bhazard(brate) /// k1(rcs1-rcs4 agegrp2 agegrp3 agegrp4 age2rcs1 age3rcs1 age4rcs1) /// k2(rcs1-rcs4 agegrp2 agegrp3 agegrp4 age2rcs1 age3rcs1 age4rcs1) predict cure, cure ci predict rs, survival ci predict rsu, survival uncured ci predict exhaz, hazard ci predict median, centile ci Paul C Lambert Cure Models and Relative Survival 12th UK Stata Users Group 14/27

Time Trends for Cancer of the Colon Age <50 1.0 Cure Fraction and Median Survival of Uncured Age Group: <50 Cure Fraction Median Survival 2.5 0.8 2.0 Cure Fraction 0.6 0.4 1.5 1.0 Median Survival 0.2 0.5 0.0 1950 1960 1970 1980 1990 2000 Year of Diagnosis 0.0 Paul C Lambert Cure Models and Relative Survival 12th UK Stata Users Group 15/27

Time Trends for Cancer of the Colon Age <50 1.0 Cure Fraction and Median Survival of Uncured Age Group: <50 Cure Fraction Median Survival 2.5 0.8 2.0 Cure Fraction 0.6 0.4 1.5 1.0 Median Survival 0.2 0.5 0.0 1950 1960 1970 1980 1990 2000 Year of Diagnosis 0.0 Paul C Lambert Cure Models and Relative Survival 12th UK Stata Users Group 15/27

Time Trends for Cancer of the Colon 1.00 0.80 <50 years 50 59 years 60 69 years 70 80 years Cure Fraction Cure Fraction 0.60 0.40 0.20 0.00 1950 1960 1970 1980 1990 2000 Year of Diagnosis Paul C Lambert Cure Models and Relative Survival 12th UK Stata Users Group 16/27

Time Trends for Cancer of the Colon 2.50 2.00 <50 years 50 59 years 60 69 years 70 80 years Median Survival of Uncured Median Survival of Uncured 1.50 1.00 0.50 0.00 1950 1960 1970 1980 1990 2000 Year of Diagnosis Paul C Lambert Cure Models and Relative Survival 12th UK Stata Users Group 16/27

Quantifying Differences 0.2 Difference in Cure Fraction (Age Group <50 Age Group 70 79) Difference in Cure Fraction 0.1 0.0 0.1 0.2 0.3 1950 1960 1970 1980 1990 2000 Years from Diagnosis Paul C Lambert Cure Models and Relative Survival 12th UK Stata Users Group 17/27

Period Analysis Long-term estimates of survival may be out-of-date. Period Analysis estimates (relative) survival by only incorporating survival experience in a recent time window[1]. Period Analysis generally estimated in lifetables, but simple to incorporate in to modelling environment[8]. In survival models period analysis can be incorporated using delayed entry techniques. Paul C Lambert Cure Models and Relative Survival 12th UK Stata Users Group 18/27

Period Analysis Subject 1 Diagnosis Death or Censoring Start and Stop at Risk Times Standard Period (0, 2) Subject 2 (0, 4) Subject 3 Subject 4 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 Year (0, 6) (0, 3) Paul C Lambert Cure Models and Relative Survival 12th UK Stata Users Group 19/27

Period Analysis Subject 1 Diagnosis Death or Censoring Start and Stop at Risk Times Standard Period (0, 2) Subject 2 (0, 4) Subject 3 Subject 4 Period of Interest 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 Year (0, 6) (0, 3) Paul C Lambert Cure Models and Relative Survival 12th UK Stata Users Group 19/27

Period Analysis Subject 1 Diagnosis Death or Censoring Start and Stop at Risk Times Standard Period (0, 2) (0, 2) Subject 2 (0, 4) (2, 4) Subject 3 Subject 4 Period of Interest 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 Year (0, 6) (0, 3) (5, 6) (, ) Paul C Lambert Cure Models and Relative Survival 12th UK Stata Users Group 19/27

Period Analysis: Cancer of the Colon.6 Cancer of the Colon: Cure Fraction.5 Cure Fraction.4.3.2.1 0 Standard Lag 10 years Period Analysis Model 1 Model 2 Model 3 1960 1970 1980 1990 2000 Year Paul C Lambert Cure Models and Relative Survival 12th UK Stata Users Group 20/27

Period Analysis: Cancer of the Colon.6 Cancer of the Colon: Cure Fraction.5 Cure Fraction.4.3.2.1 0 Standard Lag 10 years Period Analysis Model 1 Model 2 Model 3 1960 1970 1980 1990 2000 Year Paul C Lambert Cure Models and Relative Survival 12th UK Stata Users Group 20/27

Period Analysis: Cancer of the Colon.6 Cancer of the Colon: Cure Fraction.5 Cure Fraction.4.3.2.1 0 Standard Lag 10 years Period Analysis Model 1 Model 2 Model 3 1960 1970 1980 1990 2000 Year Paul C Lambert Cure Models and Relative Survival 12th UK Stata Users Group 20/27

Period Analysis: Cancer of the Colon.6 Cancer of the Colon: Cure Fraction.5 Cure Fraction.4.3.2.1 0 Standard Lag 10 years Period Analysis Model 1 Model 2 Model 3 1960 1970 1980 1990 2000 Year Paul C Lambert Cure Models and Relative Survival 12th UK Stata Users Group 20/27

Period Analysis: Cancer of the Colon.6 Cancer of the Colon: Cure Fraction.5 Cure Fraction.4.3.2.1 0 Standard Lag 10 years Period Analysis Model 1 Model 2 Model 3 1960 1970 1980 1990 2000 Year Paul C Lambert Cure Models and Relative Survival 12th UK Stata Users Group 20/27

Period Analysis: Cancer of the Colon.6 Cancer of the Colon: Cure Fraction.5 Cure Fraction.4.3.2.1 0 Standard Lag 10 years Period Analysis Model 1 Model 2 Model 3 1960 1970 1980 1990 2000 Year Paul C Lambert Cure Models and Relative Survival 12th UK Stata Users Group 20/27

More Flexible Models In some situations the Weibull distribution is not flexible enough and results in a poor fit. Usually when very high excess mortality rate in first few weeks after diagnosis. Other, more flexible, distributions can be considered LogNormal and Generalized Gamma are implemented LogNormal fits poorly due to Long tail Some Convergence problems with Generalized Gamma Two Extensions Split-time models. These split the time scale into two. Within the first time interval (up to time k) use simple parametic model for the relative survival and then fit a cure fraction model condition on survival to time k. Use a Finite Mixture of Distributions. Paul C Lambert Cure Models and Relative Survival 12th UK Stata Users Group 21/27

More Flexible Models In some situations the Weibull distribution is not flexible enough and results in a poor fit. Usually when very high excess mortality rate in first few weeks after diagnosis. Other, more flexible, distributions can be considered LogNormal and Generalized Gamma are implemented LogNormal fits poorly due to Long tail Some Convergence problems with Generalized Gamma Two Extensions Split-time models. These split the time scale into two. Within the first time interval (up to time k) use simple parametic model for the relative survival and then fit a cure fraction model condition on survival to time k. Use a Finite Mixture of Distributions. Paul C Lambert Cure Models and Relative Survival 12th UK Stata Users Group 21/27

More Flexible Models In some situations the Weibull distribution is not flexible enough and results in a poor fit. Usually when very high excess mortality rate in first few weeks after diagnosis. Other, more flexible, distributions can be considered LogNormal and Generalized Gamma are implemented LogNormal fits poorly due to Long tail Some Convergence problems with Generalized Gamma Two Extensions Split-time models. These split the time scale into two. Within the first time interval (up to time k) use simple parametic model for the relative survival and then fit a cure fraction model condition on survival to time k. Use a Finite Mixture of Distributions. Paul C Lambert Cure Models and Relative Survival 12th UK Stata Users Group 21/27

Mixture of Distributions Non-Mixture Model h(t) = h (t) ln(π)(pf z1 (t) + (1 p)f z2 (t)) This allows a much more flexible shape for the excess hazard and relative survival function[11]. Mixture of two Weibull distributions generally works well. Can also think of two groups of individuals, those who die after a short time and those who die after a longer time. Mixture Model S(t) = S (t)(π + (1 π)(ps u1 (t) + (1 p)s u2 (t))) For mixture models on relative survival scale. Mixture of two Weibull distributions generally works well. Paul C Lambert Cure Models and Relative Survival 12th UK Stata Users Group 22/27

Cancer of the Colon: Weibull and Mixture of Weibulls 1.0 0.8 Age Group 70 79 Ederer II Weibull Mixture of Weibulls Relative Survival 0.6 0.4 0.2 0.0 0 2 4 6 8 10 Years from Diagnosis Paul C Lambert Cure Models and Relative Survival 12th UK Stata Users Group 23/27

Cancer of the Colon: Weibull and Mixture of Weibulls 1.0 0.8 Age Group 70 79 Ederer II Weibull Mixture of Weibulls Relative Survival 0.6 0.4 0.2 0.0 0 2 4 6 8 10 Years from Diagnosis Paul C Lambert Cure Models and Relative Survival 12th UK Stata Users Group 23/27

Cancer of the Colon: Weibull and Mixture of Weibulls 1.0 0.8 Age Group 70 79 Ederer II Weibull Mixture of Weibulls Relative Survival 0.6 0.4 0.2 0.0 0 2 4 6 8 10 Years from Diagnosis Paul C Lambert Cure Models and Relative Survival 12th UK Stata Users Group 23/27

Cancer of the Colon: Weibull and Mixture of Weibulls 1.0 0.8 Age Group 80+ Ederer II Weibull Mixture of Weibulls Relative Survival 0.6 0.4 0.2 0.0 0 2 4 6 8 10 Years from Diagnosis Paul C Lambert Cure Models and Relative Survival 12th UK Stata Users Group 24/27

Cancer of the Colon: Weibull and Mixture of Weibulls 1.0 0.8 Age Group 80+ Ederer II Weibull Mixture of Weibulls Relative Survival 0.6 0.4 0.2 0.0 0 2 4 6 8 10 Years from Diagnosis Paul C Lambert Cure Models and Relative Survival 12th UK Stata Users Group 24/27

Cancer of the Colon: Weibull and Mixture of Weibulls 1.0 0.8 Age Group 80+ Ederer II Weibull Mixture of Weibulls Relative Survival 0.6 0.4 0.2 0.0 0 2 4 6 8 10 Years from Diagnosis Paul C Lambert Cure Models and Relative Survival 12th UK Stata Users Group 24/27

Cancer of the Colon: Excess Hazard Rate 1.5 Age Group 80+ Survival of Uncured (Weibull) Survival of Uncured (Mixture of Weibulls) Excess hazard rate 1.0 0.5 0.0 0 2 4 6 8 10 Years from Diagnosis Paul C Lambert Cure Models and Relative Survival 12th UK Stata Users Group 25/27

Cancer of the Colon: Excess Hazard Rate Age Group 80+ 3.0 Excess Hazard Rate (Mixture of Weibulls) Mixture Component 1 (37%) Mixture Component 2 (63%) Excess hazard rate 2.0 1.0 0.0 0 2 4 6 8 10 Years from Diagnosis Paul C Lambert Cure Models and Relative Survival 12th UK Stata Users Group 25/27

Summary In population based cancer studies cure is often observed. Relative survival models that explicitly allow for cure are useful for monitoring trends and differences in (relative) survival. strsnmix and strsmix fit a wide range of models. Incorporation of delayed entry models allows up-to-date estimates of cure to be obtained. Still needs to be a degree of caution When cure is not a reasonable assumption. Follow-up not long enough. Simple models may not fit the data well, but alternatives are available. When the cure fraction is high (over 75-80%). Paul C Lambert Cure Models and Relative Survival 12th UK Stata Users Group 26/27

[1] H. Brenner and O. Gefeller. Deriving more up-to-date estimates of long-term patient survival. Journal of Clinical Epidemiology, 50(2):211 216, 1997. [2] R. De Angelis, R. Capocaccia, T. Hakulinen, B. Soderman, and A. Verdecchia. Mixture models for cancer survival analysis: application to population-based data with covariates. Statistics in Medicine, 18(4):441 54, 1999. [3] P.W. Dickman, A. Sloggett, M. Hills, and T. Hakulinen. Regression models for relative survival. Statistics in Medicine, 23:41 64, 2004. [4] R. Giorgi, M. Abrahamowicz, C. Quantin, P. Bolard, J. Esteve, J. Gouvernet, and J. Faivre. A relative survival regression model using b-spline functions to model non-proportional hazards. Statistics in Medicine, 22(17):2767 84, 2003. [5] P.C. Lambert. Estimating and modelling the cure fraction in population-based cancer survival analysis. Submitted to The Stata Journal, 2006. [6] P.C. Lambert, L. K. Smith, D. R. Jones, and J.L. Botha. Additive and multiplicative covariate regression models for relative survival incorporating fractional polynomials for time-dependent effects. Statistics in Medicine, 24:3871 3885, 2005. [7] P.C. Lambert, J.R. Thompson, C. L. Weston, and P. W. Dickman. Estimating and modelling the cure fraction in population-based cancer survival analysis. Submitted to Biostatistics, 2006. [8] L. K. Smith, P. C. Lambert, J. L. Botha, and D. R. Jones. Providing more up-to-date estimates of patient survival: a comparison of standard survival analysis with period analysis using life-table methods and proportional hazards models. Journal of Clinical Epidemiology, 57(1):14 20, 2004. [9] R. Sposto. Cure model analysis in cancer: an application to data from the children s cancer group. Statistics in Medicine, 21(2):293 312, 2002. [10] A. Verdecchia, R. De Angelis, R. Capocaccia, M. Sant, A. Micheli, G. Gatta, and F. Berrino. The cure for colon cancer: results from the eurocare study. International Journal of Cancer, 77(3):322 9, 1998. [11] A.Y. Yakovlev, A.D. Tsodikov, K. Boucher, and R. Kerber. The shape of the hazard function in breast carcinoma: Curability of the disease revisited. Cancer, 85:1789 98, 1999. Paul C Lambert Cure Models and Relative Survival 12th UK Stata Users Group 27/27